DiaMedica Therapeutics Inc.
DMAC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001401040
No open-market purchases or sales by DiaMedica Therapeutics Inc. insiders were filed in the last 90 days; 88 institutions reported holding it in 13F filings for Q2 2026, worth $87.8M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding DiaMedica Therapeutics Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 32 | 36 | +4 |
| Shares | 3.49M | 4.25M | +760.1K (+21.8%) |
| Value | $15.1M | $11.0M | −$4.11M (−27.3%) |
New holders (6)
Institutions that held DiaMedica Therapeutics Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Altium Capital Management LP | 496,000 | $1.28M | 0.74% |
| Aristides Capital LLC | 106,333 | $274.3K | 0.18% |
| Millennium Management LLC | 28,672 | $74.0K | 0.00% |
| Marshall Wace, LLP | 26,745 | $69.0K | 0.00% |
| Stonebridge Capital Advisors LLC | 20,000 | $51.6K | 0.01% |
| UBS Group AG | 84 | $217 | 0.00% |
Sold out (2)
Institutions that held DiaMedica Therapeutics Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Susquehanna International Group, LLP | 16,923 | $73.1K |
| Signaturefd, LLC | 25 | $108 |